Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Investing.com -- bioAffinity Technologies Inc (NASDAQ:BIAF) stock surged 14% on Thursday after the biotechnology company announced it received a notification of allowance from the United States Patent and Trademark Office for a new patent covering its AI-built algorithm and flow cytometry platform for lung cancer detection.
The patent, titled "Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning," covers a system and method for predicting lung cancer likelihood by analyzing patient sputum samples. The company’s CyPath® Lung test uses advanced flow cytometry to detect cancer-related changes in the lung.
"Artificial intelligence was integral to the development of our CyPath® Lung test and has resulted in the detection of lung cancer at its earliest Stage 1A, a potentially curative stage," said Maria Zannes, President and CEO of bioAffinity Technologies.
The company noted that a quarter of a million Americans are expected to receive a lung cancer diagnosis in 2025, representing the leading cause of cancer death. The CyPath® Lung test is designed to help physicians determine next steps for patients with pulmonary nodules requiring follow-up.
This newly allowed U.S. patent adds to bioAffinity’s expanding global patent estate, which now includes 18 awarded and 33 pending patents across multiple countries including the U.S., Canada, China, France, Germany, Hong Kong, Italy, Japan, Mexico, Spain, Sweden, and the United Kingdom.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.